Invention Grant
- Patent Title: Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
-
Application No.: US13940091Application Date: 2013-07-11
-
Publication No.: US09695233B2Publication Date: 2017-07-04
- Inventor: Harald Duerr , Frank Herting , Christian Klein , Joerg Thomas Regula , Matthias Rueth , Kay-Gunnar Stubenrauch
- Applicant: Roche Glycart AG
- Applicant Address: CH
- Assignee: ROCHE GLYCART AG
- Current Assignee: ROCHE GLYCART AG
- Current Assignee Address: CH
- Agent Grant E. Kalinowski
- Priority: EP12176299 20120713
- Main IPC: C07K16/22
- IPC: C07K16/22 ; A61K39/395 ; A61K39/00
Abstract:
The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Public/Granted literature
- US20140017244A1 Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases Public/Granted day:2014-01-16
Information query
